To: E_K_S who wrote (67198 ) 10/27/2025 3:05:27 AM From: Johnny Canuck Respond to Johnny Caution, this stock only did $30 mil in revenue. It does not raise confidence they have the capacity to make actual chips at scale. It sounds more like a licensing play than a actual chip company -fabless or not. That means NVDA, AMD, AGO, GOOGL, AMZN, IBM or META has to license it technology.AI SRAM and APU Demand Surge GSIT's SRAM chips are gaining traction in AI workloads (e.g., generative AI training), with three straight quarters of SRAM sales growth. Partnerships like KYEC and Cadence Design Systems are fueling orders, while the Associative Processing Unit (APU) targets edge AI for drones and satellites. Q1 FY2026 revenue hit $6.3M (up 35% YoY), signaling momentum. Drives 40–50% revenue growth in FY2026–2027, scaling from $30.8M to $43.1M and overwhelming fixed costs for positive net income. Gemini-II APU Breakthrough The production-ready Gemini-II chip (shipped for proof-of-concept to a defense contractor) supports YOLO vision algorithms and large LLMs with GPU-level performance but far lower energy use. This positions GSIT in high-margin defense/edge computing (19.1% of Q1 shipments). Enables premium pricing and recurring revenue; software investments accelerate customer adoption, boosting gross margins to 60%+ by FY2027. Cornell Validation Catalyst A October 20, 2025, Cornell University study confirmed the APU matches NVIDIA GPU performance using significantly less energy, sparking a 130–200% stock surge and industry buzz as a "disruptor" in efficient AI hardware. Enhances credibility, unlocking orders and partnerships; recent $50M capital raise supports scaling production for commercial viability. Gross Margin Expansion Shift to AI/APU mix lifts margins from 49% (FY2025) to 57–60% (FY2026 guidance), with Q1 FY2026 at 58.1%. Converts revenue growth into profits: Projected gross profit rises from $17.6M (FY2026) to $25.9M (FY2027), covering OpEx. OpEx Leverage and Financial Stability OpEx held flat at ~$23M in FY2026 (R&D-focused), growing only 5% annually thereafter, while revenue scales. $22.7M cash and $37.4M equity provide runway for R&D without dilution risks. Reduces OpEx/revenue ratio from 75% (historical) to ~57% by FY2027, flipping operating losses ($-5.6M in FY2026) to gains ($1.5M in FY2027).
Caveats : Risks include production scaling delays, supply chain issues, or hype fade (e.g., one analysis calls the stock overvalued at $4.67 target). If growth moderates to 20–30%, break-even could slip to FY2028. Monitor upcoming results for validation.
